A novel risk factor for predicting anti-tuberculosis drug resistance in patients with tuberculosis complicated with type 2 diabetes mellitus

The world strives for progress towards accelerating the decline rate of tuberculosis (TB) incidence from 2% to 10% per year to reach the 2035 milestone of the End TB Strategy (WHO 2014). However, the appearance and growing incidence of drug-resistant TB impedes this progress largely. WHO estimated that in 2018, there were 484000 new cases with resistance to rifampicin (the most effective first-line drug) and 78% of these cases were multidrug-resistant TB (MDR-TB) (WHO 2019). Early and accurate diagnosis is of utmost importance to mitigate burden brought by MDR-TB (WHO 2010).
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research